Association of monocyte CCR2 expression with obesity and insulin resistance in postmenopausal women Abstract Purpose: Monocytes actively participate in in ammatory mechanisms that contribute to the development of adipose tissue dysfunction and atherogenesis. e aim of this study was to evaluate the association of monocyte CCR2 chemokine receptor expression and intracellular oxidative burst with the metabolic and in ammatory factors related to body weight.
e contribution of mononuclear-phagocyte cells to the state of chronic low-grade in ammation seems to be crucial for the link between obesity and metabolic disorders like diabetes and atherosclerosis. In obese subjects, macrophages in ltrate adipose tissue, with their proportion rising from about 10% in thin subjects to up to 40% in obese. In addition, 30% to almost 60% of upregulated genes in adipose tissue of obese subjects likely are from a macrophages source [1, 2] . Adipose tissue macrophages (ATM) derive from circulating monocytes. eir recruitment in obesity is similar to the basic in ammatory response seen in the early stages of atherogenesis [3] . e key promigratory signal is the secretion of a chemokine monocyte chemoattractant protein-1 (MCP-1), which binds to the CCR2 receptor on the monocytes and promotes monocyte activation, binding and diapedesis through the endothelium [4] . ese CCR2+ blood monocytes, unlike the CCR2− cells, have been shown to be selectively recruited and to di erentiate into pro-in ammatory tissue macrophages [5, 6] .
e spectrum of adipocytokines in obesity switches to a pro-in ammatory pattern, with higher levels of tumour necrosis factor α, interleukin-6 or MCP-1 and a lower serum concentration of the protective adiponectin. ese changes, as part of the adverse metabolic impact of obesity, are enhanced by postmenopausal central body fat redistribution [7] . Adipocytokines, together with insulin, contribute to the circulatory milieu that presumably a ects the process of monocyte activation [3] . Monocytes from obese patients were already shown to be in an activated, pro-in ammatory state by the higher level of intracellular cytokines [8] . Postmenopause was also associated with in ammatory alterations in monocytes [9] . To assess the changeable monocyte phenotype, ow cytometric expression of CCR2 receptor was analysed. Reactive oxygen species, as signal molecules, participate in monocyte activation by stimulating expression of adhesion molecules and chemokine receptors so intracellular oxidative burst was also measured [10] . e aim of this study was to evaluate the association of markers participating in monocyte activation with metabolic and in ammatory factors related to body weight. Evidence from experimental research strongly suggests the involvement of monocytes in the development of metabolic disorders. It is still unclear, however, whether this involvement can be observed in a clinical setting, particularly among postmenopausal women who might be susceptible to the increased cardiovascular risk.
Methods

Subjects
Participants were recruited consecutively among postmenopausal women (more than one year without menstrual cycles) from the outpatient endocrine clinic. Exclusion criteria were infections, blood pressure higher than 140/90 mmHg, known cardiovascular disease, diabetes (fasting blood glucose higher than 7 mmol/l or 2 hour oral glucose tolerance test higher than 11.1 mmol/l) or LDL-cholesterol (LDL-c) levels higher than 4 mmol/l. Subjects who smoked and who took hormone replacement therapy or drugs, which might interfere with inammatory and metabolic factors (non-steroidal antiin ammatory drugs, corticosteroids, statins, angiotensinconvertase inhibitors and angiotensin receptors blockers), were also excluded. Following institutional ethic rules, participants were informed about the study and signed informed consent forms.
Subjects underwent a clinical examination in order to collect demographic and clinical data. Anthropometric measurements were performed according to standard procedures. e bioelectric impedance device, Genius 220 ( Jawon Medical, Kyungsan-City, Korea), was used for body composition analysis. Body fat mass was measured in kilograms and the proportion of fat mass relative to total body mass.
e screening period for each patient was up to four days, the recruitment of all patients lasted three months and 67 participants were included in the study. Patients were divided according to body mass index (BMI) into three groups: participants with BMI from 20 to 24.99 kg/m 2 , participants with BMI from 25 to 29.99 kg/m 2 and participants with BMI greater than 30 kg/m 2 . Participants were also divided in two groups according to the median value of the homeostasis model assessment-estimated insulin resistance (HOMA-IR).
Sample collection and analysis
Laboratory investigations were performed on samples of venous blood a er 12 hours of overnight fasting. In each participant all samples were taken on the same occasion, under standardized conditions. Full blood count, glucose, C-reactive protein (CRP), cholesterol, LDL-c, HDL-cholesterol (HDL-c), triglycerides and insulin were determined on the same day by routine laboratory procedures. e blood sample for high molecular weight adiponectin (HMW adiponectin) and MCP-1according to the guidelines of the manufacturers. Insulin resistance was assessed by HOMA-IR using the formula: HOMA-IR = fasting glucose (mmol/L) × fasting insulin (µU/ml) / 22.5 [11] .
Flow cytometry e blood sample for immunophenotype and oxidative burst analysis were used immediately. e antibody CD14 APC (IQ Products, Groningen, Netherlands) was used as a marker of monocytes and expression of CCR2 antigen was determined with the CCR2 PE (R&D Systems) antibody.
uanti cation of intracellular oxidative burst was performed by ow cytometry on CD14+ cells using the 2' , 7'-dichlor uorescein diacetate (DCFH-DA) (Sigma, St. Louis, MO, USA) uorochrome, which is converted to highly uorescent 2' , 7'-dichloro uorescein (DCF) using the protocol described by Bass et al. with some modi cations (12) . For evaluation of oxidative burst of stimulated leukocytes, phorbol-12-myristate-13-acetate (PMA) (Sigma) was used. Assays were performed simultaneously on 100 µl blood samples distributed into three tubes: the rst contained 5 µM DCFH-DA, the second also contained DCFH-DA but cells were stimulated by PMA and the third as a negative control. e three tubes were incubated for 15 minutes at 37 °C. In the second tube, 100 ng/ ml PMA was then added and the incubation was continued for 15 minutes more at 37 °C. In all three tubes, 2 ml of cold PBS was added and they were kept in refrigerator for 5 minutes at 2 to 8 °C and a erwards centrifuged for 5 minutes at room temperature. e antibody CD14 APC (IQ Products) was added to the pellet in all three tubes and samples incubated in the dark for 15 minutes.
Monocyte gate was determined by forward and side scatter. In this gate, CD14+ cells were selected. uanti cation of CCR2 expression was performed by determining the proportion of positive cells (CCR2 %) for respective marker on CD14+ cells inside the monocyte gate and by determining their mean uorescence intensity (CCR2 MFI). Oxidative burst was measured by the mean uorescence intensity (MFI) of DCF dye on CD14+ cells inside the monocyte gate on nonstimulated (DCF MFI) and stimulated (DCF PMA MFI) samples.
In order to standardize measurements, MFI values have been converted into molecular equivalents of soluble uorochrome (MESF), employing calibration beads (DAKO Fluorospheres, Glostrup, Denmark).
is procedure enabled the comparison of MFI between di erent patients during the entire duration of the study. e expression of surface markers and oxidative burst were measured and analysed by Beckman Coulter Cytomics FC500 ow cytometer and the CXP soware package (Beckman Coulter, Brea, USA).
Statistical analyses
Descriptive statistics of the sample were presented as mean ± standard error of the mean. Parametric and non-parametric methods were used depending on the normality of the variable distribution. A Kolmogorov-Smirnov test was used to con rm the normal distribution of variables. Parametric Student's ttests and non-parametric Mann-Whitney U tests were used for testing the di erence between two groups. e di erence between several groups was tested by ANOVA and nonparametric Kruskal-Wallis tests. Results of linear correlation are presented by Pearson correlation coe cient (r) for normally distributed variables and by Spearman's rank correlation coecient (ρ) for variables without normal distribution. Multiple linear regression analysis was used to evaluate independent predictive variables and the optimal choice of predictors was conducted by forward stepwise regression procedure. Twosided value of P < 0.05 was considered to be signi cant. Statistical analysis of data was performed by STATISTICA 7.1 soware.
Results
Clinical and laboratory data of the whole sample of 67 patients as well as subgroups according to BMI were presented in Table 1.
Participants were also divided in two groups according to the median value of HOMA-IR ( 2.04). e di erence between the groups with lower and higher insulin resistance was found in the body weight, waist circumference, fat mass and its proportion (P < 0.05), but not in BMI. Signi cantly higher levels of triglycerides, lower levels of HDL-c and higher levels of CRP were found in the group with higher insulin resistance (P < 0.05), but there were no di erences in the absolute number of monocytes and levels of HMW adiponectin or MCP-1. Signi cant di erences were found in CCR2 expression: proportion of CCR2+cells (CCR2 %) and CCR2 MFI (P < 0.05) were higher in subjects with higher HOMA-IR. Oxidative burst in non-stimulated (DCF MFI) and stimulated monocytes (DCF PMA MFI) were also higher in these subjects (P < 0.05).
In the correlation analysis, anthropometric parameters and body composition variables were signi cantly associated with CRP correlated with all measures of obesity: body weight (r = 0.3, P = 0.023), waist circumference (r = 0.33, P = 0.012), BMI (r = 0.31, P = 0.017) and fat mass (r = 0.32, P = 0.027). CRP also signi cantly correlated with insulin (r = 0.31, P = 0.023) and inversely correlated with HDL-c (r = -0.29, P = 0.026) and HMW adiponectin (r = -0.27, P = 0.049).
e absolute number of monocytes correlated with insulin levels (r = 0.34, P = 0.011), HOMA-IR (r = 0.29, P = 0.031) and inversely correlated with HDL-c (r = -0.26, P = 0.048). Considering that there was a correlation between CRP and the number of monocytes (r = 0.3, P = 0.022), it was important to distinguish whether the association of monocytes with insulin is mediated by CRP. In partial correlation analysis, a er adjustment for insulin, the statistically signi cant relationship between CRP and monocytes (r = 0.22, P > 0.05) was lost, just as the correlation of CRP with anthropometric variables and body composition measures. When partial correlation analysis was performed with adjustment for the level of CRP, the association of insulin with the absolute number of monocytes weakened only slightly (r = 0.28, P = 0.044) and remained statistically signi cant. is result suggested that the relationship between monocytes and insulin was dependent not on CRP but on a di erent mechanism.
In Table 2 , correlations of monocyte activation variables are shown. CCR2 MFI correlated with body weight, BMI, fat mass and proportion, insulin and HOMA-IR. CCR2 % correlated with the mass and the proportion of body fat.
Oxidative burst, determined by MFI, of DCF with and without PMA stimulation correlated with anthropometric measures and the amount of body fat. No signi cant associations between monocyte activation variables and in ammatory parameters were found.
is was expected because patients with acute in ammation were not included in the study.
Finally, there was a statistically signi cant correlation between MFI and proportion of CCR2 expression with oxidative burst in monocytes.
Multiple linear regression analysis (Table 3) , with insulin level as the dependent variable, was performed. e developed model revealed that monocyte number, BMI and triglycerides were independent predictors of insulin.
ese factors accounted for 38.1% of the insulin level variation and the adjusted coe cient of determination (R ) was 0.381. Discussion e close association of low-grade in ammation with obesity and insulin resistance was evident in our cohort of postmenopausal women. CRP levels typically re ect this phenomenon and among our participants CRP correlated with measures of obesity, insulin and was inversely associated with HMW adiponectin. Dividing study sample into groups according to BMI was ine ective in discriminating in ammatory variables that refer to monocyte activation. Di erences in these variables appeared only in two groups with disparate insulin resistance. In the relationship between low-grade in ammation and insulin resistance, one element was highlighted: the number of monocytes. CRP, monocytes and insulin were all related to each other, but the association of monocytes with insulin was independent of CRP. Moreover, monocytes are an independent predictive factor in the multivariate regression model of insulin. Being independent but complementary with CRP, monocyte count re ects a di erent component of the in ammatory process and speci cally the mechanisms by which they are involved [13, 14] . Monocytes and monocyte-derived macrophages have been shown to participate in the pathogenesis of insulin resistance by supporting in ammation. e association of monocytes with insulin has been con rmed in clinical trials [15] . Monocytes are less prone to acute changes than neutrophils or leukocytes and it was observed that, among leukocytes, the biggest cardiovascular risk is brought by monocytes. e link between monocytes and insulin resistance is also supported by the independent association of monocytes with metabolic syndrome components: waist circumference, blood pressure and dyslipidemia [16] .
e association of metabolic disorders with phenotype heterogeneity of human monocyte subsets results from the subsequent involvement of chemokines, cytokines and adhesion molecules in monocyte activation [17] . A statistically signi cant correlation was found between CCR2 expression in monocytes with body weight, fat mass, but also with insulin and HOMA-IR. e association of CCR2 expression with insulin resistance has been previously recognised in subjects having more advanced metabolic disorder: higher monocyte CCR2 expression and higher serum MCP-1 were measured in patients with diabetes compared to non-diabetic patients [18] . In adipose tissue, CCR2 gene expression was elevated in obese patients compared with lean controls in both subcutaneous and visceral depot [19] . Experiments strongly support the hypothesis that CCR2 sustains both chronic in ammation and systemic insulin resistance by mediating the in ltration of inammatory ATM in adipose tissue [20] . Despite some contrary results [21] , CCR2 de ciency also attenuated ATM accumulation, while pharmacologic CCR2 antagonist reduced ATM content and improved insulin sensitivity in mice [22] . e key to this relationship among CCR2 chemokine receptor, obesity and insulin resistance is thought to be the insulinsensitizing gene transcription factor, PPARγ. Although expressed in adipocytes too, PPARγ has its dominant role in the monocyte-macrophage system [23] . PPARγ activation in monocytes and macrophages reduces the expression of many in ammatory genes, reduces the oxidative burst and secretion of in ammatory cytokines. Experiments using a ligand demonstrated the entire pathogenetic sequence: PPARγ activation of circulating monocytes suppressed the expression of CCR2 chemokine receptor, caused the rapid loss of functional CCR2 protein, inhibited the physiological response of monocytes to MCP-1 and inhibited the in ltration of adipose tissue by macrophages [24] . CCR2 seems to be an important tool by which PPARγ manages the in ammatory process, and monocyte CCR2 expression might, in fact, re ect actions of this key factor in insulin resistance. Although the design of our study does not allow for assumptions about causal relationships, the expression of CCR2 in circulating monocytes in the clinical settings ts into this paradigm.
Evaluation of monocyte activation by measurement of oxidative burst yielded correlations with anthropometric variables and measures of the fat mass in our subjects. Oxidative burst in monocytes is presumed to be one of possible pathophysiologic mediators of chronic in ammation in atherosclerosis and obesity. In the case of obese patients, it was suggested that elevated reactive oxygen species are early markers of monocytic commitment with an in ammatory phenotype [25] . Macrophages were also identi ed as being responsible for the high levels of free radicals in adipose tissue because of their high capacity of free radical production [26] . In our cohort, oxidative burst correlated with monocyte CCR2 expression, too. e use of antioxidants in vitro experiments rapidly reduced the levels of CCR2 in monocytes [27] . Additional insight into the changes of the system was provided by the use of PPARγ ligands, which demonstrated that oxidative burst in monocytes was mitigated through PPARγ agonists [28] . Although PPARγ transcription factor has only indirect impact on free radicals, through its interaction with NFκB, these ndings indicated that it might also take the part in mediating the link between CCR2 and oxidative burst. e MCP1/CCR2 system is thought to have a direct role in monocyte recruitment to the fat tissue and the arterial wall; however, our data were not able to support the relationship among circulating MCP-1, obesity-related parameters and monocyte activation. Circulating MCP-1 was found to be as- sociated with obesity in several studies, but this relationship could not be consistently reproduced even in large scale studies [29] . MCP-1 was shown to be very dependent on the impaired metabolic status and our study subjects di ered by body weight but they had neither major metabolic disorders nor evident cardiovascular diseases. A large part of MCP-1 variance may also depend on other factors because MCP-1 shows ubiquitous expression in many cell types. For instance, excess adipose tissue seems to be the primary source of MCP-1 in obesity, but in lean individuals osteoblasts are an important source of MCP-1 [30] . Adipose tissue mRNA expression of MCP-1 was determined to be correlated with obesity and this suggests that circulating MCP-1 may not be representative of the local paracrine role of MCP-1 in monocyte activation and adipose tissue in ltration [31] .
In conclusion, our study indicated important links between monocytes and obesity and, especially, insulin resistance. e number of monocytes was found to be an independent predictor of insulin level, supporting the hypothesis that monocytes play an important role in chronic in ammation in obesity. e CCR2 marker and oxidative burst in monocytes were signi cantly associated with insulin resistance, so it remains to be further elucidated how monocyte activation could contribute to the assessment and management of obesity and its comorbidities. 
